Lychee is an exotic tropical fruit with a distinct flavor. The genome of cultivar ‘Feizixiao’ was assembled into 15 pseudochromosomes, totaling ~470 Mb. High heterozygosity (2.27%) resulted in two complete haplotypic assemblies. A total of 13,517 allelic genes (42.4%) were differentially expressed in diverse tissues. Analyses of 72 resequenced lychee accessions revealed two independent domestication events. The extremely early maturing cultivars preferentially aligned to one haplotype were domesticated from a wild population in Yunnan, whereas the late-maturing cultivars that mapped mostly to the second haplotype were domesticated independently from a wild population in Hainan. Early maturing cultivars were probably developed in Guangdong via hybridization between extremely early maturing cultivar and late-maturing cultivar individuals. Variable deletions of a 3.7 kb region encompassed by a pair of CONSTANS-like genes probably regulate fruit maturation differences among lychee cultivars. These genomic resources provide insights into the natural history of lychee domestication and will accelerate the improvement of lychee and related crops.

No abstract

To find efficient ways to increase the percentage of seed germination and seedling emergence in litchi (Litchi chinensis Sonn.), we investigated the effects of soaking and high temperature on seed germination, as well as the influence of seed placement (orientation and burial depth) on seedling emergence. Seeds of most tested litchi cultivars soaked in water had a better germination performance than seeds without soaking. More than 90% germination of tested litchi seeds was obtained when the soaking times were 26–54 hours. During presprouting, short-term high temperatures (37–44 °C) exerted a negative effect on seed germination rate, but did not influence the germination percentage. In addition, high temperatures (>42 °C) compromised the further growth of sprouted litchi seeds. Burial depth and seed orientation both significantly influenced the seedling recruitment. There was a reduction in seedling emergence with an increase in burial depth. Seeds at the depth of 2 cm showed the best seedling emergence with an average percentage of 90%. Litchi seedling emergence was greatest and most rapid when seeds were sown 2 cm deep, positioned flat, on their sides, and with the radicle oriented downward.

No abstract

The characteristics of litchi pollen have drawn increasing attention in recent years. Previous studies indicated that there are significant differences in the quantity and viability of litchi pollen grains among different varieties and flowering stages. Moreover, the same variety may show a different quantity of pollen grains and viability in different years. There is still a lack of systematic studies on the change of pollen germination rate and pollen amount in different varieties and at different flowering stages. In this study, the changes in the germination rate of pollen at different development stages were studied. It was primarily revealed that the pollen germination rate already approached its peak upon the filament extends fully, but the anther does not dehisce the developmental stage. In 2009 and 2010, the viability and number of pollen grains per anther were investigated in 65 litchi cultivars, and a difference was observed among cultivars. The pollen germination rate ranged between 20.14% (‘Wuchali’) and 54.69% (‘Donlongmili’). The number of pollen grains per anther ranged between 1555 (‘Zhongshanzhuangyuanhong’) and 7455 (‘Houye’). Sixty-five litchi cultivars were classified into six clusters based on the pollen quantity and germination rate. Most litchi cultivars can produce large amounts of viable and compatible pollen grains during the flowering period. Thus, our results indicate that the pollen amount and germination rate might not be the only factors restricting the successful pollination of litchi.

ObjectivesEvidence from systematic reviews/meta-analyses about the efficacy and safety of Qishen Yiqi (QSYQ) dripping pills in chronic heart failure (CHF) remains unclear. This study comprehensively reviewed available systematic reviews on latest evidence to provide reliable information for the clinical use of QSYQ in CHF.MethodsThe systematic review was performed on studies retrieved from six major medical databases. Eligible studies were evaluated in terms of methodological quality and quality of evidence using the Assessment of Multiple Systematic review 2 (AMSTAR-2) tool, the Risk of Bias in Systematic Reviews (ROBIS) was used to assess the risk of bias, and the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) 2020 was utilized for assessing reporting quality. In addition, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to determine primary outcome indicators’ evidence quality.ResultsA total of 14 systematic reviews were included in this study, based on which it could be concluded that QSYQ combined with conventional medicine (CM) treatment tended to be superior to CM treatment alone in terms of improving cardiac function-related indices (e.g., increasing the left ventricular ejection fraction [LVEF] and reducing the left ventricular end-diastolic dimension [LVEDD] and left ventricular end-systolic internal diameter [LVESD]), improving the total effective rate and 6-min walking distance (6MWD), and reducing N-terminal pro-brain natriuretic peptide (NT-proBNP). Overall, no serious QSYQ-related adverse events were observed. However, the GRADE results showed “very low” to “moderate” evidence for these outcomes, with no high-quality evidence supporting them. Unsatisfactory results were obtained in terms of methodological quality, risk of bias and reporting quality after assessment using the AMSTAR-2, ROBIS, and PRISMA 2020, limited mainly by deficiencies in the following areas: registration of study protocols, explanation of the inclusion of randomized controlled trials (RCTs), complete and detailed search strategy, list of excluded literature, description of funding sources for inclusion in RCTs, investigation of the impact of risk of bias on the results of meta-analysis, and reporting of potential conflicts of interest.ConclusionThe efficacy and safety of QSYQ adjuvant therapy in CHF remain to be further clarified due to the lack of high-quality evidence provided by current systematic reviews.

No abstract

Background: In recent years, more and more studies revealed that liver fibrosis progression could happen at early stage in chronic hepatitis B (CHB) patients. However, there is no anti-fibrotic agent available at present in modern medicine.He-He-Shu-YangParticles (HHSYP) and Anluohuaxian Pills (AHP)are two commonly used Traditional Chinese Medicine (TCM) agents for liver fibrosis, but there is no data of them for early liver fibrosis(F1 or F2) in multicenter, randomized controlled trial. Therefore, the aim of this study is to evaluate efficacy and safety ofHHSYP plus AHP for early liver fibrosis in CHB patients. Methods/design: For the 72-week randomized controlled study, 480 CHB patients with early liver fibrosis are randomly assigned at a 2:1 ratio to two groups: the intervention group and the placebo group. The intervention group was treated with HHSYP plus AHP. The placebo group was treated with placebo of HHSYP and AHP. The primary end point is the histological change after 72-week treatment.Discussion: Although previous studies have confirmed the anti-fibrosis efficacy of HHSYP and AHP in CHB patients, the efficacy and safety of their combination treatment for early liver fibrosis is still not clear.Therefore, this will be the first multicenter randomized trial to prove the efficacy and safety of combination TCM treatment of HHSYP and AHP for early liver fibrosis, which will use histological changes as the primary end point. This will provide reliable data for the TCM combination treatment of early liver fibrosis and might give a new direction for further international studies on liver fibrosis.Ethics and dissemination: This study protocol was approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (BF2018-175-01) and all other participating centers (Project number2018ZX10725506-003).The study findings will be published in peer-reviewed journals and presented at the national and international conferences. Trial registration: Chinese Clinical Trial Registration: ChiCTR1900025897, Registered:13 September 2019, http://www.chictr.org.cn/edit.aspx?pid=40222&htm=4